Vital radioisotope for cancer treatments will be produced using High-Flux Reactor in Petten
Nuclear medicine company Curium has signed a long-term agreement to extend its current partnership with NRG Pallas for new irradiation services at Petten, the Netherlands, to produce non-carrier added lutetium-177 (Lu-177).
